May 2004
Volume 45, Issue 13
Free
ARVO Annual Meeting Abstract  |   May 2004
Combined Transpupillary Thermotherapy Enhanced with Indocyanine Green and Intravitreal Triamcinolone Acetonide for Choroidal Neovascularization in Age–related Macular Degeneration
Author Affiliations & Notes
  • E.P. Jablon
    Ophthalmology, Retina Consultants of Charleston / Medical University of S. Carolina, Charleston, SC
  • A. Lavaque
    Ophthalmology, New England Retina Associates, Hamden, CT
  • N. Chaudhry
    Ophthalmology, Yale University School of Medicine, New Haven, CT
  • D. Tom
    Ophthalmology, Yale University School of Medicine, New Haven, CT
  • D.V. Alfaro
    Ophthalmology, Retina Consultants of Charleston / Medical University of S. Carolina, Charleston, SC
  • H. Quiroz–Mercado
    Retina Service, Universidad Nacional Autonoma de Mexico, Mexico City, Mexico
  • P. Liggett
    Ophthalmology, New York Hospital–Cornell Medical Center, New York, NY
  • Footnotes
    Commercial Relationships  E.P. Jablon, None; A. Lavaque, None; N. Chaudhry, None; D. Tom, None; D.V. Alfaro, None; H. Quiroz–Mercado, None; P. Liggett, None.
  • Footnotes
    Support  none
Investigative Ophthalmology & Visual Science May 2004, Vol.45, 5126. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      E.P. Jablon, A. Lavaque, N. Chaudhry, D. Tom, D.V. Alfaro, H. Quiroz–Mercado, P. Liggett; Combined Transpupillary Thermotherapy Enhanced with Indocyanine Green and Intravitreal Triamcinolone Acetonide for Choroidal Neovascularization in Age–related Macular Degeneration . Invest. Ophthalmol. Vis. Sci. 2004;45(13):5126.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Abstract: : Purpose: : A preliminary study to examine combined modality treatment consisting of transpupillary thermotherapy enhanced with indocyanine green (I–TTT) and intravitreal triamcinolone acetonide for subfoveal choroidal neovascularization (CNV) secondary to age–related macular degeneration (AMD) in patients who were not candidates for PDT with Visudyne. Methods: This is a retrospective, non–comparative case study. Sixteen eyes of 15 patients with a mean age of 80 years (range 69 – 92) with subfoveal CNV secondary to AMD, who were not candidates for treatment with PDT using Visudyne, were treated with I–TTT followed by an intravitreal injection of 4 mg (0.1cc) of triamcinolone acetonide. The mean follow–up was 6 months (range 3 – 12). Baseline parameters of visual acuity assessment (Snellen chart), fundus examination, fundus photography and angiography with fluorescein and indocyanine green were performed at baseline and at 3, 6, 9 and 12 months after de–enrollment. The need for re–treatment was based on fluorescein angiograpic evidence of leakage at 3 month follow–up intervals. The incidence of adverse events associated with treatment was also observed. Results: Of the 16 eyes, 11 (69%) maintained or had improved visual acuity at the third month of the treatment, with the trend continuing in longer term follow–up. Five eyes suffered visual loss (two or more lines), two of them with heavy pigmented areas or extensive signs of retinal pigment epithelial atrophy. Fifteen of the 16 eyes showed regression of the CNV with a decrease in subretinal exudation during the follow–up. Six (37.5%) eyes required re–treatment and seven (44%) patients required one topical antihypertensive agent to control their intraocular pressure. No patients developed endophthalmitis or retinal detachment. Conclusions: Although this was a small preliminary study with limited follow–up, the results indicate that I–TTT plus intravitreal triamincinolone may be a reasonable alternative in cases of CNV due to AMD in patients who are not candidates for conventional focal laser photocoagulation or PDT using Visudyne.

Keywords: age–related macular degeneration • laser • choroid: neovascularization 
×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×